Agency Report
The coronavirus vaccine developed jointly by BioNTech and Pfizer is “still effective” against the Omicron variant of the virus after three doses, the German company said in a statement on Wednesday.
An Omicron-specific version of the jab, currently in development by BioNTech, would be available “by March,” it added.
AFP